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Abstract
Introduction: Fibrosis in scleroderma is associated with collagen deposition and myofibroblast accumulation.
Peroxisome proliferator activated receptor gamma (PPAR-g), a master regulator of adipogenesis, inhibits profibrotic
responses induced by transforming growth factor-ß (TGF-b), and its expression is impaired in scleroderma. The
roles of adiponectin, a PPAR-g regulated pleiotropic adipokine, in regulating the response of fibroblasts and in
mediating the effects of PPAR-g are unknown.
Methods: Regulation of fibrotic gene expression and TGF-ß signaling by adiponectin and adenosine
monophosphate protein-activated (AMP) kinase agonists were examined in normal fibroblasts in monolayer
cultures and in three-dimensional skin equivalents. AdipoR1/2 expression on skin fibroblasts was determined by
real-time quantitative PCR.
Results: Adiponectin, an adipokine directly regulated by PPAR-g, acts as a potent anti-fibrotic signal in normal and
scleroderma fibroblasts that abrogates the stimulatory effects of diverse fibrotic stimuli and reduces elevated
collagen gene expression in scleroderma fibroblasts. Adiponectin responses are mediated via AMP kinase, a fuel-
sensing cellular enzyme that is necessary and sufficient for down-regulation of fibrotic genes by blocking canonical
Smad signaling. Moreover, we demonstrate that endogenous adiponectin accounts, at least in part, for the anti-
fibrotic effects exerted by ligands of PPAR-g.
Conclusions: These findings reveal a novel link between cellular energy metabolism and extracellular matrix
homeostasis converging on AMP kinase. Since the levels of adiponectin as well as its receptor are impaired in
scleroderma patients with progressive fibrosis, the present results suggest a potential role for defective adiponectin
expression or function in progressive fibrogenesis in scleroderma and other chronic fibrosing conditions. Restoring the
adiponectin signaling axis in fibroblasts might, therefore, represent a novel pharmacological approach to controlling
fibrosis.
Introduction
Scleroderma or systemic sclerosis (SSc) is a chronic auto-
immune disease associated with fibrosis in multiple organs
[1]. Fibrosis in the skin is due to overproduction of col-
lagen and other extracellular matrix (ECM) components
by activated fibroblasts accompanied by progressive loss of
subcutaneous adipose tissue [2]. Transforming growth fac-
tor-b (TGF-b) is a key mediator of fibrosis that initiates
and sustains fibroblast activation and myofibroblast differ-
entiation [3]. A variety of cell-autonomous regulatory
mechanisms exist to control fibroblast activation and
prevent aberrant constitutive fibrogenesis. Peroxisome
proliferator-activated receptor gamma (PPAR-g) is a pleio-
tropic nuclear receptor implicated in the regulation of
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adipogenesis [4]. Emerging evidence also implicates PPAR-
g in ECM accumulation and connective tissue homeosta-
sis, and natural and synthetic PPAR-g ligands are potent
inhibitors of fibrotic responses [5].
Adiponectin is a multi-functional 30 kD adipokine that
regulates insulin sensitivity, energy balance and cellular
metabolism [6]. The expression of adiponectin is tightly
regulated by PPAR-g, and its levels in circulation are
decreased in patients with obesity, type 2 diabetes and
metabolic syndrome [7]. In contrast, serum levels are
raised by PPAR-g agonist treatment in mice and in
humans [8]. Significantly, recent studies demonstrate that
adiponectin levels are reduced in patients with diffuse
cutaneous scleroderma, and are inversely correlated with
disease activity, severity and duration [9-12]. These
observations point to a potential role for adiponectin in
the pathogenesis of scleroderma, but the underlying
mechanisms are not currently understood.
The mechanisms of action accounting for the metabolic
effects of adiponectin have been extensively characterized
[13,14]. Biological activity is initiated through adiponectin
binding to the cell membrane receptors AdipoR1,
AdipoR2 and T-cadherin. The central modulator of the
adiponectin signaling cascade is AMP kinase, a key inter-
mediate in cellular energy metabolism [15]. Binding of
AMP induces AMP kinase phosphorylation and activation,
which both promotes catabolic energy-producing path-
ways and inhibits anabolic energy-consuming pathways
[16]. Whereas the importance of deregulated adiponectin
and AMP kinase signaling in metabolic diseases has been
long appreciated [17], AMP kinase function in the context
of fibrogenesis has not been thoroughly addressed,
although emerging evidence suggests that adiponectin
might play a significant role. Adiponectin and AMP kinase
activation inhibit hepatic stellate cell proliferation and
attenuate liver fibrosis [18-20]. In other studies, adiponec-
tin was shown to prevent cardiomyocyte hypertrophy and
myocardial fibrosis [21-23].
Fibrosis in scleroderma is associated with impaired
PPAR-g expression and activity and reduced adiponectin
levels, which may be a direct consequence of the PPAR-g
defect [11,12,24,25]. In light of these intriguing recent
observations, we sought to gain a better understanding of
the role of adiponectin in the modulation of collagen
synthesis and myofibroblast differentiation in fibroblasts.
Results using two-dimensional monolayer cultures and
three-dimensional full-thickness human skin equivalents
demonstrate that adiponectin potently suppressed the
expression of Type I collagen and a-smooth muscle actin
(a-SMA) in normal and scleroderma fibroblasts, and
abrogated the stimulation of these responses elicited by
TGF-b. The inhibitory effects of adiponectin were
mediated by activation of AMP kinase. Moreover, genetic
deletion of adiponectin in mouse fibroblasts abrogated
the inhibition of TGF-b signaling elicited by PPAR-g
agonists. The expression of adiponectin receptor 1 was
selectively reduced in skin biopsies from patients with
scleroderma. Taken together, these findings indicate that
the adiponectin/AMP kinase pathway may play a pre-
viously unrecognized important homeostatic role in ECM
regulation, and its defective function contributes to aber-
rant fibroblast activation in the pathogenesis of fibrosis.
The adiponectin signaling pathway, therefore, represents
a novel therapeutic target in scleroderma.
Materials and methods
Cell culture and reagents
Primary fibroblast cultures were established by explanta-
tion from neonatal foreskin biopsies, or from skin biopsies
from healthy adults and scleroderma patients obtained
under the protocols approved by the Institutional Review
Board at Northwestern University. All donors or their par-
ents/legal guardians provided written informed consent.
Mouse skin fibroblasts were established by explant culture
from three-week-old adiponectin-null mice and wild-type
littermates [26]. Fibroblasts were maintained in (D)MEM)
supplemented with 10% fetal bovine serum (FBS) (Lonza,
Basel, Switzerland), 50 μg/ml penicillin, and 50 μg/ml
streptomycin in a humidified atmosphere of 5% CO2 at
37°C, and studied between passages 2 to 8 [27]. When
fibroblasts reached confluence, growth media with 10%
FBS or serum-free media supplemented with 0.1% BSA
were added to the cultures for 24 hours prior to TGF-b2
(Peprotech, Rocky Hill, NJ, USA), or full-length adiponec-
tin (Bio Vendor, Karasek, Czech Republic). In selected
experiments, the AMP-activated protein kinase (AMPK)
inhibitor Compound C (Sigma, St Louis, MO, USA) was
added to the culture 60 minutes prior to adiponectin.
Toxicity was determined using lactate dehydrogenase
(LDH) assays according to the manufacturer’s instructions
(Biovision, Milpitas, CA, USA).
Three-dimensional full-thickness human skin equivalents
Normal skin fibroblasts (3 × 105) were suspended in 1.5 ml
reconstitution buffer and (D)MEM. Cells were mixed with
rat tail type I collagen (4 mg/ml, BD Biosciences, San Jose,
CA, USA) and seeded in 12-well plates at 37°C for 48
hours to solidify the collagen plug. Epidermal keratinocytes
(6 × 106) were isolated from foreskin and suspended in
E medium supplemented with 5 ng/ml epidermal growth
factor (EGF) and seeded on the collagen plug [28,29].
Forty eight hours later, organotypic cultures were placed
on a metal grid (BD Biosciences) and maintained at an
air-medium interface by feeding with E medium every
other day for five days. Metformin (1 mM) was added
to the media for 24 hours followed by TGF-b (5 ng/ml).
Following incubation for a further six days, cultures were
harvested, RNA was isolated, and tissues were fixed in
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formalin. Paraffin-embedded sections (4 μm thickness)
were examined by Picrosirius Red staining.
Short interfering RNA-mediated knockdown and
adenovirus infection
Fibroblasts were transfected with target-specific siRNA
(Dharmacon, Lafayette, CO, USA) or scrambled control
siRNA (10 nM). Twenty-four hours following transfection,
fresh media were added to the cultures, and the incuba-
tions were continued for a further 24 hours. Knockdown
efficiency was evaluated by determining endogenous
mRNA levels by real-time qPCR.
RNA isolation and real-time quantitative PCR (qPCR)
At the end of each experiment, cultures were harvested,
RNA was isolated using RNeasy Plus mini kits (Qiagen,
Valencia, CA, USA) and examined by real-time quantita-
tive qPCR [30]. Experiments were repeated three times
with consistent results. The primers used for qPCR are
shown in Table 1.
Microarray procedures and data analysis
Expression of AdipoR1/2 mRNA was interrogated in
publicly available genome-wide expression scleroderma
skin microarray datasets (GEO accession number:
GSE9285) [31].
Transient transfection assays
Fibroblasts at early confluence were transfected with [SBE]
4-luc plasmids harboring four copies of a minimal Smad-
binding element using SuperFect Transfection kit (Qiagen)
as described [32]. Cultures were incubated in serum-free
media containing 0.1% BSA for 24 hours, followed by
TGF-b2 for a further 24 hours and harvested. Whole cell
lysates were assayed for their luciferase activities using a
dual-luciferase reporter assay system (Promega, Madison,
WI, USA). In each experiment, Renilla luciferase pRL-TK
(Promega) was cotransfected as control for transfection
efficiency [33]. Transient transfection experiments were
performed in triplicate and repeated at least twice with
consistent results.
Confocal immunofluorescence microscopy
Fibroblasts (1 × 104 cells/well) were seeded onto eight-well
Lab-Tek II chamber glass slides (Nalge Nunc International,
Naperville, IL, USA) and incubated in serum-free Eagle’s
minimal essential medium (EMEM) with 0.1% BSA for
24 hours. Fresh media with adiponectin (5 ug/ml) were
added, and the incubations continued for a further
24 hours. At the end of the experiments, cells were fixed,
permeabilized, and incubated with primary antibodies to
Type I collagen at 1:500 dilution (Southern Biotech,
Birmingham, AL, USA), or to a-SMA at 1:200 dilution
(Sigma, St Louis, MO, USA). Cells were then washed with
PBS and incubated with secondary antibodies at 1:500 dilu-
tion (Alexa Fluor 488 and 594, Invitrogen) and viewed
under a Nikon C1Si confocal microscope.
Western analysis
At the end of each experiment, fibroblasts were harvested
and whole cell lysates subjected to Western analysis as
described [30]. The following antibodies were used: Type
I collagen (Southern Biotech), a-SMA (Sigma), and
GAPDH (Zymed, San Francisco, CA, USA). Bands were
visualized using ECL reagents (Pierce, Rockford, IL, USA).
Statistical analysis
Statistical analysis was performed on Excel (Microsoft,
Redmond, WA, USA) using Student t-test or analysis of
variance (ANOVA). The results are shown as the means ±
SEM. P <0.05 was considered statistically significant.
Results
Adiponectin inhibits collagen and alpha-smooth muscle
actin gene expression
To investigate the regulation of fibrotic gene expression
by adiponectin, foreskin fibroblasts were maintained in
two-dimensional monolayer cultures. At confluence, cul-
tures were incubated in media with an increasing con-
centration of adiponectin for 24 hours, and changes in
gene expression were examined by real-time qPCR,
Western analysis and immunocytochemistry. The results
demonstrated a dose-dependent inhibition of Col1A1
Table 1 Primers used for real-time qPCR.
Gene Primer sequences Accession number
18S rRNA olg1, 5’-CCCCATGAACGAGGGAATT-3’ olg2, 5’-GGGACTTAATCAACGCAAGCTT-3’ NR_003286
GAPDH olg3, 5’-CATGAGAAGTATGACAACAGCCT-3’ olg4, 5’-AGTCCTTCCACGATACCAAAGT-3’ NM_002046
ACTA2 (a-SMA) olg20, 5’-CAGGGCTGTTTTCCCATCCAT-3’ olg21, 5’-GCCATGTTCTATCGGGTACTTC-3’ NM_001613
COL1A1 olg149, 5’-GCTGGTGTGATGGGATTC-3’ olg150, 5’-GGGAACACCTCGCTCT-3’ NM_000088
AdipoR1 olg396, 5’-TGACTGGCTAAAGGACAACG-3’ olg397, 5’-AAAAGAGAAACAGCACGAAACC-3’ NM_015999
AdipoR2 olg400, 5’-CAGCCATTATAGTCTCCCAGTG-3’ olg401, 5’-CCGAGATGACATAGTGCAAGG-3’ NM_024551
Glut4 olg404, 5’-ACTGGACGAGCAACTTCATC-3’ olg405, 5’-GAGGACCGCAAATAGAAGGAA-3’ NM_001042
Primer sequences were obtained using Primer Express 3.0 software.
Most primer pairs span two exons, except the intronless 18S rRNA. Primers were tested by dissociation curve analysis to assure only single amplicon.
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and a-SMA gene expression, with a >60% reduction at
24 hours (Figure 1 and data not shown). Potent inhibition
of Type I collagen and a-SMA by adiponectin was
confirmed by Western analysis and immunostaining
(Figure 1). Comparable results were observed in normal
adult dermal fibroblasts (data not shown). Expression
of both AdipoR1 and AdipoR2 mRNA in explanted
fibroblasts was confirmed by real-time qPCR. Next, we
investigated the effect of recombinant adiponectin in
scleroderma fibroblasts. Confluent scleroderma fibroblasts
(n = 4, Table 2) were incubated with adiponectin for 36
hours, and cell lysates were used for Western analysis.
Results showed that adiponectin induced an approximately
40% decrease in collagen gene expression (Figure 1D).
Adiponectin attenuates TGF-b-induced profibrotic
responses
In light of the fundamental role of TGF-b in orchestrating
fibrogenesis, it was of interest to evaluate how adiponectin
modulated relevant responses elicited by TGF-b. For this
purpose, normal fibroblasts in two-dimensional monolayer
cultures were pretreated with adiponectin followed by
incubation with TGF-b for a further 24 hours. The results
of real-time qPCR showed that adiponectin caused a dose-
dependent attenuation of collagen and a-SMA gene
expression induced by TGF-b, with an almost 50% reduc-
tion at 10 μg/ml (Figure 2A). Of note, adiponectin induced
an approximately four-fold increase in the levels of the
TGF-b pseudoreceptor BMP and activin membrane-
bound inhibitor (BAMBI), which negatively regulates
TGF-b responses. To examine the possible role of endo-
genous adiponectin in modulating the intensity of TGF-b
responses, we used an RNAi approach. The results showed
that siRNA-mediated effective knockdown of adiponectin
in fibroblasts significantly increased the basal levels of
Type I collagen and a-SMA mRNA and protein (1.5-fold
and 1.8-fold, respectively). Moreover, adiponectin-depleted
fibroblasts were hypersensitive to TGF-b treatment, with
significantly enhanced stimulation of collagen and a-SMA
gene expression compared to fibroblasts transfected with
Figure 1 Adiponectin inhibits collagen and alpha-smooth muscle actin gene expression. Confluent control (A-C) or scleroderma (D)
dermal fibroblasts were incubated with adiponectin (5 ug/ml) for 24 to 36 hours. A. Total RNA was subjected to real-time qPCR. The results
represent the means ± SEM of triplicate determinations. * P <0.05, ** P <0.01. B, D. Whole cell lysates were analyzed by Western blot.
Representative autoradiographs. C. Fibroblasts were immunostained with antibodies to Type I collagen (red) or a-SMA (green), or stained with
DAPI (blue), and examined by confocal microscopy. Representative immunofluorescence photomicrographs. Original magnification × 60. a-SMA,
a-smooth muscle actin; DAPI, 4’,6-diamidino-2-phenylindole; SEM, standard error of the mean.
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control siRNA, suggesting an inhibitory function for endo-
genous adiponectin in setting the intensity of TGF-b
signaling.
Agonists of AMP kinase inhibit fibrotic gene expression
and abrogate TGF-b responses
In mesenchymal cells, adiponectin induces AMP kinase
activity ([34] and data not shown). To investigate the
role of AMP kinase in modulating fibrotic gene expres-
sion, fibroblasts were incubated with the selective AMP
kinase agonists 5-amino-1-b-D-ribofuranosyl-imidazole-
4-carboxamide (AICAR) or metformin. The results of
real-time qPCR demonstrated a potent dose-dependent
inhibition of Col1A1 and Col1A2 mRNA expression,
with a nearly 90% reduction at 5 mM of the AMP
kinase antagonists (Figure 3). There was no evidence of
cellular toxicity even at the highest concentrations of
AICAR or metformin tested (data not shown). In addi-
tion to collagen, multiple genes implicated in fibrogen-
esis showed substantial decrease in expression. To
establish the specificity of the anti-fibrotic activity of
AMP kinase agonists, we examined the expression of
the insulin-regulated glucose transporter GLUT4, a tar-
get gene positively regulated by AMP kinase [35]. As
expected, AICAR induced a substantial increase in
Figure 2 Adiponectin attenuates TGF-b-induced profibrotic responses. A. Confluent dermal fibroblasts were incubated with or without TGF-
b (2 ng/ml) in the presence of the indicated concentration of adiponectin for 48 hours. Total RNA was subjected to real-time qPCR. The results
represent the means ± SEM of triplicate determinations. B. Fibroblasts were preincubated with adiponectin-specific siRNA or control siRNA. SEM,
standard error of the mean; TGF-b, transforming growth factor b
Table 2 Clinical features of SSc patients.





S902 54 F lcSSc Early* 1 12
S903 39 F dcSSc Late 5 19
S904 33 F dcSSc Late 9 N/A
S1004 27 F dcSSc Late 10 26
S1066 21 M dcSSc Early 2 15
S1156 48 F SSc/PM Early 1 20
S1302 51 F lcSSc Early 2 4
*early = < 2 years from first non-Raynaud symptom at the time of skin biopsy.
Fibroblasts from N900-1016 and S902-1004 were used for real-time qPCR
analysis. Fibroblasts from S1004-1302 were used for Western blot analysis.
MRSS, Modified Rodnan skin score; SSc, systemic sclerosis.
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Figure 3 AMP kinase agonists inhibit profibrotic gene expression. Confluent dermal fibroblasts in two-dimensional monolayer cultures
were incubated with the indicated concentrations of (A) AICAR or (B) metformin for 24 hours. Total RNA was subjected to real-time qPCR.
The results represent the means ± SEM of triplicate determinations. C. Fibroblasts were immunostained with antibodies to Type I collagen
(red), or stained with DAPI (blue). Representative immunofluorescence photomicrographs. Original magnification ×60. D. Fibroblasts
transiently transfected with (SBE)4-luc were pre-treated with AICAR or metformin (1 mM) for 24 hours, followed by TGF-b (10 ng/ml) for
24 hours. Cell lysates were assayed for their luciferase activities. The results represent the means ± SEM of triplicate determinations. AICAR,
5-amino-1-b-D-ribofuranosyl-imidazole-4-carboxamide; DAPI, 4’,6-diamidino-2-phenylindole; SEM, standard error of the mean; TGF-b,
transforming growth factor-b.
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GLUT4 mRNA expression. Both AMP kinase agonists
potently attenuated the fibrotic responses induced by
TGF-b (data not shown). To investigate the mechanism,
transient transfection assays were performed. The results
showed that adiponectin incubation resulted in disrup-
tion of canonical Smad signaling, as shown in transient
transfection assays with the Smad-responsive minimal
promoter (SBE)4-luc (Figure 3D).
The organotypic raft culture (ORC) model is a three-
dimensional full-thickness human skin equivalent that is
a powerful approach to studying fibroblast function in
the context of fibrogenesis [28]. This full thickness
human skin equivalent model allows us to examine fibro-
blast behavior where the biomechanical forces impacting
the fibroblasts are relevant to the physiologically relevant
context of skin [28]. The three-dimensional full-thickness
skin equivalents were incubated with metformin (1 mM)
with or without TGF-b (5 ng/ml) for six days. Results
from real-time qPCR showed that while TGF-b induced
a substantial increase in fibrotic gene expression, treat-
ment with metformin abrogated the effect (Figure 4A).
Picrosirius Red staining showed that TGF-b induced a
notable accumulation of strongly birefringent red col-
lagen fibers, indicating highly cross-linked collagen, in
the dermal compartment. In contrast, pretreatment of
the rafts with metformin prevented collagen maturation,
with a predominance of green, less cross-linked collagen
fibers (Figure 4B), confirming that metformin abrogated
TGF-b induced collagen protein accumulation.
To directly examine the role of AMP kinase in mediat-
ing the antifibrotic effects of adiponectin, a chemical
inhibitor of AMP kinase activity was used [36]. In fibro-
blasts preincubated with Compound C, a selective and
potent AMP kinase inhibitor, the inhibitory effects of
adiponectin on TGF-b-induced collagen and a-SMA
mRNA and protein were completely abrogated (Figure 5).
Adiponectin mediates the anti-fibrotic effects of PPAR-g
ligands
We have shown previously that both pharmacological
and endogenous ligands of PPAR-g inhibited collagen
gene expression, and abrogated the stimulation of fibrotic
Figure 4 AMP kinase agonists attenuate TGF-b-induced profibrotic responses in three-dimensional full-thickness human skin
equivalents. Fibroblasts embedded in three-dimensional full-thickness skin equivalents were incubated with metformin (1 mM) with or without
TGF-b (5 ng/ml) for six days. At the end of the experiments, rafts were harvested. A. Real-time qPCR. The results represent the means ± SEM of
triplicate determinations. B. 4-μm thick paraffin-embedded sections were stained with Picrosirius Red. Mature highly cross-linked collagen fibers
in the dermal compartment appear red when visualized under polarized light, whereas less mature collagen fibers containing few cross-links
appear yellow/green. Representative images (original magnification ×40). SEM, standard error of the mean; TGF-b, transforming growth factor-b.
Fang et al. Arthritis Research & Therapy 2012, 14:R229
http://arthritis-research.com/content/14/5/R229
Page 7 of 13
responses elicited by TGF-b [37]. Moreover, rosiglita-
zone, a PPAR-g ligand inhibited the over-expression of
fibrotic genes in fibroblasts explanted from scleroderma
patients [24]. The anti-fibrotic activities of these ligands
were blocked by the irreversible PPAR-g antagonist
GW9662, indicating that they were largely PPAR-g-
dependent [38]. Adiponectin is a direct transcriptional
target of PPAR-g, and its expression in both adipocytes
and fibroblasts is tightly regulated via activated PPAR-g
binding to cognate DNA recognition sequences in the
adiponectin gene promoter [11,39]. In order to investi-
gate the potential role of endogenous adiponectin in
mediating the anti-fibrotic effects of PPAR-g ligands, we
examined the effect of prostaglandin J2 (PGJ2) in adipo-
nectin-null mouse skin fibroblasts. Consistent with the
results using RNAi, we found that collagen and a-SMA
gene expression were significantly elevated in both unsti-
mulated and TGF-b-stimulated fibroblasts lacking adipo-
nectin compared to wild type control fibroblasts,
confirming the significant role of cellular adiponectin in
modulating the intensity of TGF-b-induced fibrotic
responses (Figure 6). Importantly, while PGJ2 elicited
substantial down-regulation of TGF-b responses in wild
type fibroblasts, as shown previously [25], no significant
PGJ2 effect on the stimulatory response was seen in adi-
ponectin-null fibroblasts.
Adiponectin attenuates LPS-induced profibrotic responses
We next sought to determine if the anti-fibrotic effects of
adiponectin were specific for TGF-b, or more generalized
for other profibrotic stimuli. To this end, fibroblasts were
incubated with lipopolysaccharide (LPS), a potent ligand
of Toll-like receptor 4 (TLR4). LPS induced a time-
dependent stimulation of collagen and aSMA gene
expression in normal fibroblasts (Figure 7 and data not
shown). However, pretreatment of the cultures with
adiponectin completely abrogated the stimulatory effects
of LPS.
Adiponectin receptor expression in scleroderma
Adiponectin-induced cellular responses are mediated
through activation of the adiponectin receptors AdipoR1
and AdipoR2 [40]. In order to investigate the adiponectin
signaling axis in scleroderma, we examined AdipoR
expression. Fibroblasts were explanted from skin biopsies
from the affected lesional forearm of four patients with
scleroderma (Table 2), and age and sex-matched healthy
controls (n = 4) and grown to confluence, when total
RNA was isolated and subjected to real-time qPCR. The
results showed approximately 40% lower levels of Adi-
poR1 mRNA in scleroderma fibroblasts compared to
normal fibroblasts, but the differences were not statisti-
cally significant (P = 0.22) (Figure 8). AdipoR2 levels
were comparable in scleroderma and control fibroblasts.
To evaluate AdipoR1/2 mRNA expression in sclero-
derma skin, the expression of these genes was interrogated
in a publicly available microarray dataset examining gene
expression in skin [31]. Biopsies clustering within the
diffuse and inflammatory intrinsic subsets [31] showed
an approximately 30% reduction in AdipoR1 (P <0.05),
Figure 5 AMP kinase mediates suppression of profibrotic responses by adiponectin. Confluent dermal fibroblasts in two-dimensional
monolayer cultures were incubated with adiponectin (5 ug/ml) in media with TGF-b (2 ng/ml) in the presence or absence of Compound C (10
uM) for 48 hours. Total RNA was harvested and subjected to real-time qPCR. The results represent the means ± SEM of triplicate determinations.
SEM, standard error of the mean; TGF-b, transforming growth factor-b.
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with a slight reduction in AdipoR2 (P = ns) expression
compared to biopsies clustering with the normal-like sub-
set (Figure 8B).
Discussion
Persistence of activated myofibroblasts in response to
chronic TGF-ß signaling underlies the progression of
fibrosis in scleroderma [2]. We have demonstrated that
PPAR-g activation by endogenous ligands or pharmaco-
logical agonists exerts potent inhibitory effects on col-
lagen gene expression and myofibroblast differentiation,
and blocks TGF-ß-induced profibrotic responses, in
mesenchymal cells in vitro [37,38]. Moreover, the
PPAR-g ligand rosiglitazone was shown to prevent and
attenuate the development of dermal fibrosis in mice
[41]. Significantly, recent studies have revealed a marked
impairment of PPAR-g expression and activity in skin
biopsies from subsets of patients with scleroderma [25].
Moreover, explanted scleroderma fibroblasts showed
reduced PPAR-g [24]. We have previously identified a
scleroderma subset with impaired PPAR-g signaling that
was associated with a strong ‘TGF-ß-activated gene sig-
nature’ in skin biopsies [42]. These scleroderma patients
had a rather aggressive form of disease with extensive
skin fibrosis. While these findings strongly implicate
aberrant PPAR-g function in the persistent fibrosis of
scleroderma, the underlying molecular mechanisms
remain to be elucidated.
The present studies showed that the PPAR-g-regulated
adipokine adiponectin caused a marked inhibition of
collagen gene expression and myofibroblast differentia-
tion in neonatal and normal adult skin fibroblasts as
well as in scleroderma fibroblasts. Significantly, these
inhibitory effects occurred at adiponectin concentrations
Figure 6 Adiponectin mediates the anti-fibrotic effects of PPAR-g ligands. Dermal fibroblasts from adiponectin-null mice and wild-type
littermates in parallel were incubated with indicated concentrations of PGJ2, followed by TGF-b (2 ng/ml) for 24 hours. Total RNA was subjected
to real-time qPCR. The results represent the means ± SEM of triplicate determinations. PGJ2, prostaglandin J2; SEM, standard error of the mean;
TGF-b, transforming growth factor-b.
Figure 7 Adiponectin attenuates LPS-induced profibrotic
responses. Confluent dermal fibroblasts were incubated with LPS
(1 ug/ml) in the absence or presence of adiponectin (10 ug/ml) for
24 hours. Total RNA was subjected to real-time qPCR. The results
represent the means ± SEM of triplicate determinations. LPS,
lipopolysaccharide; SEM, standard error of the mean.
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approximating physiological plasma levels (5 to 20 μg/ml)
[11,43]. Adiponectin stimulated the expression of
BAMBI, an endogenous negative regulator of Smad-
dependent signaling, while blocking fibrotic responses
elicited by TGF-b, as well as by the TLR4 ligand LPS.
While TGF-b-induced collagen production and myofi-
broblast transformation are known to be mediated via
the canonical Smad signaling pathway [44], the mechan-
ism underlying the fibrotic responses elicited by TLR4
ligands remain incompletely understood. A comparable
antagonism between adiponectin and LPS was described
in the context of LPS-dependent fibrogenesis in adventi-
tial fibroblasts [45]. The inhibitory effects of adiponectin
on fibrotic responses were associated with activation of
AMP kinase, a stress-induced metabolic master switch
that plays a key role in maintaining energy homeostasis.
By detecting and responding to cellular nutrient and
energy fluctuations, heterotrimeric AMP kinase promotes
catabolic energy-producing pathways to enhance cellular
glucose uptake, fatty acid oxidation, and GLUT4
biogenesis [46]. In the present studies, pharmacological
AMP kinase agonists mimicked the inhibitory effect of
adiponectin on profibrotic gene expression and Smad-
dependent signaling, while the selective AMP kinase inhi-
bitor Compound C rescued TGF-b stimulation of fibrotic
genes in the presence of adiponectin. Moreover, transient
transfection experiments indicate that AMP kinase
attenuation resulted in abrogation of canonical Smad-
dependent TGF-b signaling. While previous studies have
highlighted the anti-inflammatory, anti-oxidant and fatty
Figure 8 Adiponectin receptor expression in scleroderma. A. Total RNA was isolated from confluent fibroblasts explanted from scleroderma
patient (n = 4) and healthy controls (n = 4), and subjected to real-time qPCR. The results represent the mean ± SEM of triplicate determinations.
B. AdipoR1/2 mRNA expression was interrogated in publicly available genome-wide expression scleroderma skin biopsy microarray datasets (GEO
accession number: GSE9285) [31]. Fold-change in mRNA levels was normalized with average expression levels of the samples in the entire
cohort. Box plots indicate the range of lower and upper quartiles. * P <0.05. SEM, standard error of the mean.
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acid-regulating activities of AMP kinase [18,47], the pre-
sent studies reveal important functions for adiponectin in
modulating fibrogenesis. The mechanism underlying the
anti-fibrotic activities of adiponectin and their signifi-
cance in health and fibrosis remains to be elucidated.
Adiponectin is an adipocyte-derive pleiotropic hormone
with key protective roles in diabetes and atherosclerosis
[17,48,49]. Sequence-specific recognition of the adiponec-
tin gene promoter PPRE element by activated PPAR-g
results in enhanced adiponectin transcription [7]. Recent
studies expand the spectrum of the biological activities
ascribed to adiponectin, including important roles in regu-
lating inflammation and cancer [50]. Cellular adiponectin
responses are mediated via the seven transmembrane
domain type 1 and type 2 adiponectin receptors as well
as T-cadherin [17]. Obesity is associated with reduced
expression of adiponectin receptors in various tissues,
contributing to a state of adiponectin resistance [51].
We and others have shown that adiponectin levels are
reduced in the serum and lesional skin from patients
with scleroderma [10-12]. Adiponectin levels were inver-
sely correlated with the skin score, a measure of fibrotic
skin involvement, and scleroderma patients with the
most extensive skin fibrosis had the lowest adiponectin
levels [11]. Moreover, patients responding to anti-fibro-
tic treatment with improved skin scores or lung function
displayed a time-dependent increase in serum adiponec-
tin levels [11,12].
The important role for adiponectin in negative regula-
tion of connective tissue remodeling suggested by these
findings is concordant with recent observations. For
instance, adiponectin was shown to down-regulate con-
nective tissue growth factor expression in hepatocytes and
hepatic stellate cells, and blocked the stimulatory effect
elicited by TGF-ß [52,53]. We have shown that, although
adiponectin is primarily produced by adipocytes, its
expression is detectable, and strongly up-regulated by
PPAR-g ligand in normal dermal fibroblasts [11]. Signifi-
cantly, both RNAi-mediated adiponectin knockdown in
normal fibroblasts and genetic depletion of adiponectin in
mouse fibroblasts was associated with increased collagen
and a-SMA gene expression. Moreover, adiponectin-
depleted fibroblasts were sensitized to the profibrogenic
effects of TGF-ß. These in vitro findings are concordant
with in vivo observations that adiponectin-null mice devel-
oped exaggerated liver fibrosis when challenged with
thioacetamide [54,55]. Moreover, adiponectin-deficient
hepatic stellate cells failed to respond to the PPAR-g ligand
troglitazone in vitro. Together with these observations, our
present results indicate that adiponectin plays an impor-
tant homeostatic role in negative regulation of collagen
deposition and myofibroblast accumulation, and that
the anti-fibrotic effects associated with endogenous and
pharmacological ligands of PPAR-g are due, at least in
part, to activation of the adiponectin/AMP kinase signal-
ing pathway as illustrated in Figure 9. In addition, because
scleroderma is associated with impaired PPAR-g activity
[11,24,25], reduced adiponectin levels in scleroderma
patients are likely to result from impaired PPAR-g activity.
Considered in the light of these findings, hypo adiponectin
coupled with reduced AdipoR1 expression in scleroderma
patients with early diffuse disease suggest that attenuated
adiponectin signaling is a risk factor directly contributing
to the failure to control aberrant fibrogenic responses,
resulting in persistent fibroblast activation and sustained
collagen production and myofibroblast differentiation.
Indeed, low adiponectin levels and reduced adiponectin
receptor expression are associated with accelerated devel-
opment of liver fibrosis in patients with chronic hepatitis
C infection [56]. Moreover, low adiponectin or AdipoR1
have been shown to predict progression of hepatic steato-
sis to cirrhosis [57].
The inverse correlation between adiponectin signaling
and fibrogenesis in scleroderma in the aforementioned
studies suggests a potential role for adiponectin in the
pathogenesis of skin fibrosis. We are struck by the par-
allels between reduced adiponectin and disappearance of
fat tissue in liver fibrosis on the one hand, where quies-
cent fat-strong hepatic stellate cells transition into fibro-
genic myofibroblasts with down-regulation of PPAR-g,
and loss of subcutaneous adipose tissue associated with
dermal fibrosis in patients with scleroderma. These par-
allels raise the intriguing possibility that subcutaneous
adipocytes fulfill a role for analogues to that of the
hepatic stellate cells of the skin.
Conclusions
Pharmacological activation of the adiponectin pathway
has potent anti-fibrotic effects in normal and sclero-
derma fibroblasts, and represents an exciting potential
Figure 9 Adiponectin suppresses fibrotic responses. Ligands of
PPAR-g induce adiponectin which triggers autocrine or paracrine
activation of AMP kinase. AMP kinase in turn blocks TGF-b/Smad
signaling and consequent stimulation of profibrotic gene
expression. PPAR-g, peroxisome proliferator activated receptor
gamma; TGF-b, transforming growth factor-b.
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therapeutic approach to the control of dermal fibrosis in
scleroderma.
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